Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 51
Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report References Agol, V.I. 2002. Picornavirus genome: an overview. In Molecular Biology of Picornaviruses. B.L. Semler and E. Wimmer, Eds. ASM Press, Washington, DC. Alexander, J.P., Jr., H.E. Gary, Jr., and M.A. Pallansch. 1997. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. Journal of Infectious Diseases 175:S176-S182. Andino, R., G.E. Rieckhof, and D. Baltimore. 1990. A functional ribonucleoprotein complex forms around the 5' end of poliovirus RNA. Cell 63:369-380. Andries, K., B. Dewindt, J. Snoeks, L. Wouters, H. Moereels, P.J. Lewi, and P.A.J. Janssen. 1990. Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogenicity. Journal of Virology 64(3):1117-1123. Andries, K., B. Dewindt, J. Snoeks, R. Willebrords, K. Van Eemeren, R. Stokbroekx, and P.A.J. Janssen. 1992. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrobial Agents and Chemotherapy 36(1):100-107. Arita, M., S.L. Zhu, H. Yoshida, T. Yoneyama, T. Miyamura, and H. Shimizu. 2005. A Sabin 3-derived poliovirus recombinant contained a sequence homologous with indigenous human enterovirus species C in the viral polymerase coding region. Journal of Virology 79(20):12650-12657. Arora, V., G.R. Devi, and P.L. Iversen. 2004. Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics. Current Pharmaceutical Biotechnology 5(5):431-439. Aylward, R.B., and S.L. Cochi. 2004. Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild poliovirus transmission. Bulletin of the World Health Organization 82:40-46. Aylward, R.B., R.W. Sutter, and D.L. Heymann. 2005. OPV cessation—the final step to a “polio-free” world. Science 310(5748):625-626.
OCR for page 52
Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report Baltimore, D., M.F. Jacobson, J. Asso, and A.S. Huang. 1969. The formation of poliovirus proteins. Cold Spring Harbor Symposium in Quantitative Biology 34:741-746. Binford, S.L., F. Maldonado, M.A. Brothers, P.T. Weady, L.S. Zalman, J.W. Meador, 3rd, D.A. Matthews, and A.K. Patick. 2005. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrobial Agents and Chemotherapy 49(2):619-626. Bodian, D. 1952. Experimental studies on passive immunization against poliomyelitis. II. The prophylactic effect of human gamma globulin on paralytic poliomyelitis in cynomolgus monkeys after virus feeding. American Journal of Hygiene 56:78-89. Bodian, D. 1955. Emerging concept of poliomyelitis infection. Science 122:105. Bodian, D., and D.M. Horstmann. 1965. Polioviruses. In Viral and Rickettsial Infections of Man, fourth ed. F.L. Horsfall, Jr. and I. Tamm, Eds. J.B. Lippincott, Philadelphia. Carr, J., J. Ives, L. Kelly, R. Lambkin, J. Oxford, D. Mendel, L. Tai, and N. Roberts. 2002. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Research 54(2):79-88. CDC (Centers for Disease Control and Prevention). 2005a. Conclusions and recommendations of the advisory committee on poliomyelitis eradication—Geneva, Switzerland, October 2005. Morbidity and Mortality Weekly Report 54(46):1186-1188. CDC. 2005b. Poliovirus infections in four unvaccinated children—Minnesota, August-October 2005. Morbidity and Mortality Weekly Report 54(41):1053-1055. Census Bureau, Population Division, International Programs Center. 2005. IDB Summary Demographic Data. Accessed online 12/16/05 at http://www.census.gov/ipc/www/idbsum.html. Coffin, J.M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267(5197):483-489. Collett, M.S. 2005. Capsid inhibitors: a path to polio antiviral drugs. Presented at the Workshop on Development of a Polio Antiviral, National Research Council, November 1, 2005, Washington, DC. Crotty, S., D. Maag, J.J. Arnold, W. Zhong, J.Y. Lau, Z. Hong, R. Andino, and C.E. Cameron. 2000. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nature Medicine 6(12):1375-1379. Erratum in: Nature Medicine 7(2):255. Crowder, S., and K. Kirkegaard. 2005. Trans-dominant inhibition of RNA viral replication can slow growth of drug-resistant viruses. Nature Genetics 37(7):665-666. de la Torre, J.C., E. Wimmer, and J.J. Holland. 1990. Very high frequency of reversion to guanidine resistance in clonal pools of guanidine-dependent type 1 poliovirus. Journal of Virology 64(2):664-667. DiMasi, J.A., R.W. Hansen, and H.G. Grabowski. 2003. The price of innovation: new estimates of drug development costs. Journal of Health Economics 22:151-185. Domingo, E., J. Holland, and P. Ahlquist. 1988. RNA Genetics. CRC Press, Boca Raton. Duintjer Tebbens, R.J., M.A. Pallansch, O.M. Kew, V.M. Caceres, R.W. Sutter, and K.M. Thompson. 2005. A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. American Journal of Epidemiology 162(4):358-372.
OCR for page 53
Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report Egger, D., R. Gosert, and K. Bienz. 2002. Role of cellular structures in viral RNA replication. In Molecular Biology of Picornaviruses. B.L. Semler and E. Wimmer, Eds. ASM Press, Washington, DC. Eigen, M. 1993. Viral quasispecies. Scientific American 269(1):42-49. Fairbrother, R.W., and E.W. Hurst. 1930. The pathogenesis of experimental poliomyelitis. Journal of Pathology and Bacteriology 33:17-45. Fenner, F., D.A. Henderon, I. Arita, Z. Jezek, and I.D. Ladnyi. 1988. Smallpox and its eradication. World Health Organization, Geneva. Filman, D.J., R. Syed, M. Chow, A.J. Macadam, P.D. Minor, and J.M. Hogle. 1989. Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus. The EMBO Journal 8:1567-1579. Flanegan, J.B., and D. Baltimore. 1977. Poliovirus-specific primer-dependent RNA polymerase able to copy poly(A). Proceedings of the National Academy of Sciences of the United States of America 74(9):3677-3680. Franco, D., H.B. Pathak, C.E. Cameron, B. Rombaut, E. Wimmer, and A.V. Paul. 2005. Stimulation of poliovirus RNA synthesis and virus maturation in a HeLa cell-free in vitro translation-RNA replication system by viral protein 3CDpro. Virology Journal 2:86. Frank, R.G. 2003. New estimates of drug development costs. Journal of Health Economics 22:325-330. Gitlin, L., S. Karelsky, and R. Andino. 2002. Short interfering RNA confers intracellular antiviral immunity in human cells. Nature 418:430-434. Global Polio Eradication Initiative. 2006. Donor Contributions and Projections to Polio Eradication 1985-2008. Accessed online 2/16/06 at http://www.polioeradication.org/content/general/HistContributionWebJan06.pdf. Gnann, J.W., Jr., C.S. Crumpacker, J.P. Lalezari, J.A. Smith, S.K. Tyring, K.F. Baum, M.J. Borucki, W.P. Joseph, G.J. Mertz, R.T. Steigbigel, G.A. Cloud, S.J. Soong, L.C. Sherrill, D.A. DeHertogh, and R.J. Whitley. 1998. Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Antimicrobial Agents and Chemotherapy 42(5):1139-1145. Grant, R.A., C.N. Hiremath, D.J. Filman, R. Syed, K. Andries, and J.M. Hogle. 1994. Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design. Current Biology 4(9):784-797. Halsey, N.A., J. Pinto, F. Espinosa-Rosales, M.A. Faure-Fontenla, E. da Silva, A.J. Khan, A.D.B. Webster, P. Minor, G. Dunn, E. Asturias, H. Hussain, M.A. Pallansch, O.M. Kew, J. Winkelstein, R. Sutter, and the Polio Project Team. 2004. Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil and the United Kingdom. Bulletin of the World Health Organization 82:3-8. Hellen, C.U., M. Facke, H.G. Krausslich, C.K. Lee, and E. Wimmer. 1991. Characterization of poliovirus 2A proteinase by mutational analysis: residues required for auto-catalytic activity are essential for induction of cleavage of eukaryotic initiation factor 4F polypeptide p220. Journal of Virology 65(8):4226-4231.
OCR for page 54
Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report Hiremath, C.N., R.A. Grant, D.J. Filman, and J.M. Hogle. 1995. Binding of the antiviral drug WIN51711 to the Sabin strain of type 3 poliovirus: structural comparison with drug binding in rhinovirus 14. Acta Crystallographica Section D-Biological Crystallography 51(4):473-489. Hiremath, C.N., D.J. Filman, R.A. Grant, and J.M. Hogle. 1997. Ligand-induced conformational changes in poliovirus-antiviral drug complexes. Acta Crystallographica Section D-Biological Crystallography 53(5):558-570. Hirst, G. 1962. Genetic recombination with Newcastle disease virus, polioviruses, and influenza. Cold Spring Harbor Symposium. Quantitative Biology 27:303-308. Hogle, J.M., M. Chow, and D.J. Filman. 1985. Three-dimensional structure of poliovirus at 2.9 A resolution. Science 229:1358-1365. Holland, J., K. Spindler, F. Horodyski, E. Grabau, S. Nichol, and S. VandePol. 1982. Rapid evolution of RNA genomes. Science 215(4540):1577-1585. Holland, J.J., J.C. de la Torre, and D.A. Steinhauer. 1992. RNA virus populations as quasispecies. Current Topics in Microbiology and Immunology 176:1-20. Horie, H., S. Koike, T. Kurata, Y. Sato-Yoshida, I. Ise, Y. Ota, S. Abe, K. Hioki, H. Kato, and C. Taya. 1994. Transgenic mice carrying the human poliovirus receptor: new animal models for study of poliovirus neurovirulence. Journal of Virology 68:681-688. Horstmann, D.M., R. Ward, and J.L. Melnick. 1946. The isolation of poliomyelitis virus from human extra-neural sources. III. Persistence of virus in stools after acute infection. Journal of Clinical Investigation 25:278-283. Jackson, W.T., T.H. Giddings, Jr., M.P. Taylor, S. Mulinyawe, M. Rabinovitch, R.R. Kopito, and K. Kirkegaard. 2005. Subversion of cellular autophagosomal machinery by RNA viruses. PLoS Biology 3(5):e156. Joseph-McCarthy, D., S.K. Tsang, D.J. Filman, J.M. Hogle, and M. Karplus. 2001. Use of MCSS to design small targeted libraries: application to picornavirus ligands. Journal of the American Chemical Society 123(51):12758-12769. Kew, O.M., R.W. Sutter, B.K. Nottay, M.J. McDonough, D.R. Prevots, L. Quick, and M.A. Pallansch. 1998. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. Journal of Clinical Microbiology 36:2893-2899. Kew, O., V. Morris-Glasgow, M. Landaverde, C. Burns, J. Shaw, Z. Garib, J. Andre, E. Blackman, C.J. Freeman, J. Jorba, R. Sutter, G. Tambini, L. Venczel, C. Pedreira, F. Laender, H. Shimizu, T. Yoneyama, T. Miyamura, H. van Der Avoort, M.S. Oberste, D. Kilpatrick, S. Cochi, M. Pallansch, and C. de Quadros. 2002. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 296:356-359. Kew, O.M., P.F. Wright, V.I. Agol, F. Delpeyroux, H. Shimizu, N. Nathanson, and M.A. Pallansch. 2004. Circulating vaccine-derived polioviruses: current state of knowledge. Bulletin of the World Health Organization 82(1):16-23. Kew, O.M., R.W. Sutter, E.M. de Gourville, W.R. Dowdle, and M.A. Pallansch. 2005. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annual Review of Microbiology 59:587-635. Kirkegaard, K., and D. Baltimore. 1986. The mechanism of RNA recombination in poliovirus. Cell 47:433-443.
OCR for page 55
Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report Kitamura, N., B.L. Semler, P.G. Rothberg, G.R. Larsen, C.J. Adler, A.J. Dorner, E.A. Emini, R. Hanecak, J.J. Lee, S. van der Werf, C.W. Anderson, and E. Wimmer. 1981. Primary structure, gene organization and polypeptide expression of poliovirus RNA. Nature 291(5816):547-553. Koike, S., H. Horie, I. Ise, A. Okitsu, M. Yoshida, N. Iizuka, K. Takeuchi, T. Takegami, and A. Nomoto. 1990. The poliovirus receptor protein is produced both as membrane-bound and secreted forms. EMBO Journal 9:3217-3224. Kuechler, E., J. Seipelt, H.D. Liebig, and W. Sommergruber. 2002. Picornavirus-mediated proteinase shut-off of host cell translation: direct cleavage of a cellular initiation factor. In Molecular Biology of Picornaviruses. B.L. Semler and E. Wimmer, Eds. ASM Press, Washington, DC. Lentz, K.N., A.D. Smith, S.C. Geisler, S. Cox, P. Buontempo, A. Skelton, J. Demartino, E. Rozhon, J. Schwartz, V. Girijavallabhan, J. O’Connell, and E. Arnold. 1997. Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973: comparison of the structural and biological properties of three poliovirus serotypes. Structure 5(7):961-978. Leong, L.E.C., C.T. Cornell, and B.L. Semler. 2002. Processing determinants and functions of cleavage products of picornavirus proteins. In Molecular Biology of Picornaviruses. B.L. Semler and E. Wimmer, Eds. ASM Press, Washington, DC. MacLennan, C., G. Dunn, A.P. Huissoon, D.S. Kumararatne, J. Martin, P. O’Leary, R.A. Thompson, H. Osman, P. Wood, P. Minor, D.J. Wood, and D. Pillay. 2004. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet 363:1509-1513. Martin, J., K. Odoom, G. Tuite, G. Dunn, N. Hopewell, G. Cooper, C. Fitzharris, K. Butler, W.W. Hall, and P.D. Minor. 2004. Long-term excretion of vaccine-derived poliovirus by a healthy child. Journal of Virology 78:13839-13847. Melnick, J.L. 1996. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses, vol. 1. In Virology, third ed. B.N. Fields, Ed. Raven Press, New York. Mendelsohn, C.L., E. Wimmer, and V.R. Racaniello. 1989. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin super family. Cell 56:855-865. Minor, P. 1997. Poliovirus. In Viral Pathogenesis. N. Nathanson, Ed. Lippincott-Raven, Philadelphia. Molla A., A.V. Paul, and E. Wimmer. 1991. Cell-free, de novo synthesis of poliovirus. Science 254(5038):1647-1651. Molla, A., A.V. Paul, M. Schmid, S.K. Jang, and E. Wimmer. 1993. Studies on dicistronic polioviruses implicate viral proteinase 2Apro in RNA replication. Virology 196(2):739-747. Mosimann, S.C., M.M. Cherney, S. Sia, S. Plotch, and M.N. James. 1997. Refined X-ray crystallographic structure of the poliovirus 3C gene product. Journal of Molecular Biology 273(5):1032-1047. Mueller, S., E. Wimmer, and J. Cello. 2005. Poliovirus and poliomyelitis: a tale of guts, brains, and an accidental event. Virus Research 111:175-193. Nathanson, N. 2005. David Bodian’s contribution to the development of poliovirus vaccine. American Journal of Epidemiology 161:207-212.
OCR for page 56
Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report Nathanson, N., and J.R. Martin. 1979. The epidemiology of poliomyelitis: enigmas surrounding its appearance, epidemicity, and disappearance. American Journal of Epidemiology 110(6):672-692. Nicklin, M.J., K.S. Harris, P.V. Pallai, and E. Wimmer. 1988. Poliovirus proteinase 3C: large-scale expression, purification, and specific cleavage activity on natural and synthetic substrates in vitro. Journal of Virology 62(12):4586-4593. Olsen, D.B., A.B. Eldrup, L. Bartholomew, B. Bhat, M.R. Bosserman, A. Ceccacci, L.F. Colwell, J.F. Fay, O.A. Flores, K.L. Getty, J.A. Grobler, R.L. LaFemina, E.J. Markel, G. Migliaccio, M. Prhavc, M.W. Stahlhut, J.E. Tomassini, M. MacCoss, D.J. Hazuda, and S.S. Carroll. 2004. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrobial Agents and Chemotherapy 48(10):3944-3953. Parsley, T.B., J.S. Towner, L.B. Blyn, E. Ehrenfeld, and B.L. Semler. 1997. Poly (rC) binding protein 2 forms a ternary complex with the 5'-terminal sequences of poliovirus RNA and the viral 3CD proteinase. RNA 3(10):1124-1134. Patick, A.K., S.L. Binford, M.A. Brothers, R.L. Jackson, C.E. Ford, M.D. Diem, F. Maldonado, P.S. Dragovich, R. Zhou, T.J. Prins, S.A. Fuhrman, J.W. Meador, L.S. Zalman, D.A. Matthews, and S.T. Worland. 1999. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrobial Agents and Chemotherapy 43:2444-2450. Patick, A.K., M.A. Brothers, F. Maldonado, S. Binford, O. Maldonado, S. Fuhrman, A. Petersen, G.J. Smith 3rd, L.S. Zalman, L.A. Burns-Naas, and J.Q. Tran. 2005. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrobial Agents and Chemotherapy 49:2267-2275. Paul, A. 2002. Possible unifying mechanism of picornavirus genome replication. In Molecular Biology of Picornaviruses. B.L. Semler and E. Wimmer, Eds. ASN Press, Washington, DC. Paul, A.V., J.H. van Boom, D. Filippov, and E. Wimmer. 1998. Protein primed RNA synthesis by purified poliovirus RNA polymerase. Nature 393(6682):280-284. Paul, A.V., E. Rieder, D.W. Kim, J.H. van Boom, and E. Wimmer. 2000. Identification of an RNA hairpin in poliovirus RNA that serves as the primary template in the in vitro uridylylation of VPg. Journal of Virology 74(22):10359-10370. Petersen, J.F., M.M. Cherney, H.D. Liebig, T. Skern, E. Kuechler, and M.N. James. 1999. The structure of the 2A proteinase from a common cold virus: a proteinase responsible for the shut-off of host-cell protein synthesis. EMBO Journal 18(20):5463-5475. Pfeiffer, J.K., and K. Kirkegaard. 2005. Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice. PLoS Pathogens 1(2):e11. Pfister, T., and E. Wimmer. 1999. Characterization of the nucleoside triphosphatase activity of poliovirus protein 2C reveals a mechanism by which guanidine inhibits poliovirus replication. Journal of Biological Chemistry 274(11):6992-7001. Racaniello, V. 2001. Picornaviridae: the viruses and their replication. In Field Virology. P. Howley and D. Knipe, Eds. Lippinkott, Williams and Wilkins, Philadelphia. Racaniello, V.R., and D. Baltimore. 1981. Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. Proceedings of the National Academy of Sciences of the United States of America 78:4887. Reichert, J.M. 2001. Monoclonal antibodies and the clinic. Nature Biotechnology 19:819-822.
OCR for page 57
Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report Rinaldo, C.R. 2005. Passive immunization against poliomyelitis: the Hammon gamma globulin field trials, 1951-1953. American Journal of Public Health 95(5):790-799. Romanova, L.I., E.A. Talskaya, M.S. Kolesnikova, and V.I. Agol. 1980. Biochemical evidence for intertypic genetic recombination of poliovirus. FEBS Letters 118:109-112. Rossmann, M.G. 2002. Picornavirus structure overview. In Molecular Biology of Picornaviruses. B.L. Semler and E. Wimmer, Eds. ASM Press, Washington, DC. Rossmann, M.G., J. Bella, P.R. Kolatkar, Y. He, E. Wimmer, R.J. Kuhn, and T.S. Baker. 2000. Cell recognition and entry by rhino- and enteroviruses. Virology 269:239-247. Sabin, A.B. 1956. Pathogenesis of poliomyelitis; reappraisal in the light of new data. Science 123:1151-1157. Sabin, A., and R. Ward. 1941. Nature of non-paralytic and transitory paralytic poliomyelitis in rhesus monkeys inocculated with human virus. Journal of Experimental Medicine 73:757-770. Semler, B.L., and E. Wimmer, Eds. 2002. Molecular Biology of Picornaviruses. ASM Press, Washington, DC. Simoes, E.A.F, B. Padmini, M.C. Steinhoff, M. Jadhav, and T.J. John. 1985. Antibody response of infants to two doses of inactivated poliovirus vaccine of enhanced potency. American Journal of Diseases of Children 139:977-980. Skern, T., B. Hampölz, A. Guarne, I. Fita, E. Bergmann, J. Petersen, and M.N.G. James. 2002. Structure and function of picornavirus proteinases. In Molecular Biology of Picornaviruses. B.L. Semler and E. Wimmer, Eds. ASM Press, Washington, DC. Sormunen, H., M. Stenvik, J. Eskola, and T. Hovi. 2004. Age- and dose-interval-dependent antibody responses to inactivated poliovirus vaccine. Journal of Medical Virology 63:305-310. Stanway, G., T. Hovi, N.G. Knowles. 2002. Hyppiä. Molecular and biological basis of picornavirus taxonomy. In Molecular Biology of Picornaviruses. B.L. Semler and E. Wimmer, Eds. ASM Press, Washington, DC. Sutter, R. 2005. Antiviral compounds for polio eradication. Presented at the Workshop on Development of a Polio Antiviral, National Research Council, November 1, 2005, Washington, DC. Svitkin, Y.V., A.E. Gorbalenya, Y.A. Kazachkov, and V.I. Agol. 1979. Encephalomyocarditis virus-specific polypeptide p22 possessing a proteolytic activity: preliminary mapping on the viral genome. FEBS Letters 108:6-9. Thompson, A.A., and O.B. Peersen. 2004. Structural basis for proteolysis-dependent activation of the poliovirus RNA-dependent RNA polymerase. EMBO Journal 23(17):3462-3471. Tolskaya, E., L. Romanova, W. Kolesnikova, and V.I. Agol. 1983. Intertypic recombination in poliovirus: genetic and biochemical studies. Virology 123:121-132. Toyoda, H., M.J. Nicklin, M.G. Murray, C.W. Anderson, J.J. Dunn, F.W. Studier, and E. Wimmer. 1986. A second virus-encoded proteinase involved in proteolytic processing of poliovirus polyprotein. Cell 45:761-770. Vignuzzi, M., J.K. Stone, and R. Andino. 2005. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. Virus Research 107(2):173-181.
OCR for page 58
Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report Weidman, M.K., R. Sharma, S. Raychaudhuri, P. Kundu, W. Tsai, and A. Dasgupta. 2003. The interaction of cytoplasmic RNA viruses with the nucleus. Virus Research 95(1-2):75-85. Wenner, H.A., A. Kamitsuka, M. Lenahan, and I. Archetti. 1959. The pathogenesis of poliomyelitis, site of multiplication of poliovirus in cynomolgus monkeys after alimentary infection. Archiv fur die Gesamte Virusforschung 9:537-558. WHO (World Health Organization). Polio Weekly Global Update, December 21, 2005. WHO, Geneva. Wimmer, E., C.U.T. Hellen, and X. Cao. 1993. Genetics of poliovirus. Annual Review of Genetics 273:353-436. Wu, J.Z., N. Yao, M. Walker, and Z. Hong. 2005. Recent advances in discovery and development of promising therapeutics against hepatitis C virus NS5B RNA-dependent RNA polymerase. Mini Reviews in Medicinal Chemistry 5(12):1103-1112. Yang, Y., R. Rijnbrand, S. Watowich, and S.M. Lemon. 2004. Genetic evidence for an interaction between a picornaviral cis-acting RNA replication element and 3CD protein. Journal of Biological Chemistry 279(13):12659-12667. Yeung, M.L., Y. Bennasser, S.Y. Le, and K.T. Jeang. 2005. siRNA, miRNA and HIV: promises and challenges. Cell Research 15(11-12):935-946. Ypma-Wong, M.F., P.G. Dewalt, V.H. Johnson, J.G. Lamb, and B.L. Semler. 1988. Protein 3CD is the major poliovirus proteinase responsible for cleavage of the P1 capsid precursor. Virology 166:265-270.
Representative terms from entire chapter: